Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

465
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
465
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

354
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

558
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
558
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

538
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Intra-coronary imaging and transcriptomics of calcified nodules before and after intensive lipid-lowering therapy: a YELLOW III substudy.

European heart journal. Imaging methods and practice·2026
Same author

Restoration of Limb Alignment in Post-Traumatic Genu Varum Case Using Medial Open Wedge Proximal Tibial Osteotomy with Posterior Tibial Slope Correction: A Case Report.

Journal of orthopaedic case reports·2026
Same author

Standard modifiable risk factors among patients undergoing percutaneous coronary intervention: prevalence and impact.

European heart journal·2026
Same author

TOPSIS-Based Performance and Drilling Delamination Assessment of Chemically Treated PALF Composites for Lightweight UAVs.

ACS omega·2026
Same author

The Electrophysiology Experience in Patients With Ebstein's Anomaly Undergoing the da Silva Cone Repair at UPMC Children's Hospital of Pittsburgh.

Journal of cardiovascular electrophysiology·2026
Same author

Association of Proteinuria With Disease Stage and Treatment Response in Patients With Lymphoma: A Prospective Cohort Study.

Cureus·2026

相关实验视频

Updated: Mar 7, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

药物涂层的气球超越了静脉静脉复原.

Rahul Gupta1, Chandrashekar Bohra2, Krishna Santosh Vemuri3

  • 1Department of General Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Reviews in cardiovascular medicine
|March 6, 2026
PubMed
概括

药物涂层气球 (DCB) 在干预心脏病学中提供了一个有前途的无支架替代方案. 有证据支持它们用于各种冠状动脉病变,可能降低与支架相关的风险.

关键词:
用药物涂层的气球.毒品排放气球可以释放毒品.药物释放的支架可以释放药物.双重抗血小板疗法 双重抗血小板疗法

更多相关视频

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.6K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.1K

相关实验视频

Last Updated: Mar 7, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K
A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application
06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

5.6K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

17.1K

科学领域:

  • 干预心脏病学 干预心脏病学
  • 心血管器械 心血管器械

背景情况:

  • 药物涂层气球 (DCB) 越来越多地因其在干预心脏病学中的治疗潜力而得到认可.
  • 来自试验和元分析的现有证据支持DCB作为冠状动脉病变的无支架替代品.
  • DCB的目的是减轻像支架血栓和支架静止 (ISR) 这样的风险,并为高出血风险 (HBR) 患者提供更短的双重抗血小板治疗.

研究的目的:

  • 提供药物涂层气球 (DCB) 治疗的全面审查.
  • 探索DCB的不断变化的作用和扩展的迹象,超越静脉静脉复缩 (ISR).

主要方法:

  • 随机试验,观察性研究和元分析的审查.
  • 对支持DCB疗效的临床证据的分析.
  • 评估DCB在各种冠状动脉损伤类型中的应用.

主要成果:

  • DCBs在广泛的冠状动脉病变中表现出有效性.
  • DCBs为传统的支架策略提供了一个可行的替代方案.
  • 新出现的证据支持DCB在新发病变,分叉病,HBR患者和急性冠状动脉综合征中的使用.

结论:

  • 药物涂层气球 (DCB) 是干预心脏病学的重大进展.
  • DCBs提供了一个有价值的无支架选择,具有不断扩大的临床应用.
  • 预计DCB疗法将在ISR之外进行进一步的研究和临床采用.